| 產(chǎn)品編號(hào) | bs-8357R-Gold |
| 英文名稱 | Rabbit Anti-UBE2C/Gold Conjugated antibody |
| 中文名稱 | 膠體金標(biāo)記的泛素蛋白連接酶C抗體 |
| 別 名 | Cyclin selective ubiquitin carrier protein; dJ447F3.2; Mitotic specific ubiquitin conjugating enzyme; UB E2C; UBCH 10; UBCH10; UBE 2C; Ube2c; UBE2C_HUMAN; Ubiquitin carrier protein C; Ubiquitin carrier protein E2 C; Ubiquitin carrier protein E2C; Ubiquitin conjugating enzyme E2 C; Ubiquitin conjugating enzyme E2C; Ubiquitin protein ligase C; Ubiquitin-conjugating enzyme E2 C; Ubiquitin-protein ligase C. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買(mǎi) 大包裝/詢價(jià) |
| 說(shuō) 明 書(shū) | 100ul（10nm 15nm 35nm） |
| 研究領(lǐng)域 | 細(xì)胞生物 免疫學(xué) 表觀遺傳學(xué) |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Sheep, ) |
| 產(chǎn)品應(yīng)用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 20kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human UBE2C |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產(chǎn)品介紹 |
background: The ubiquitin (Ub) pathway involves three sequential enzymatic steps that facilitate the conjugation of Ub and Ub-like molecules to specific protein substrates. The first step requires the ATP-dependent activation of the Ub C-terminus and the assembly of multi-Ub chains by the Ub-activating enzyme known as the E1 component. The Ub chain is then conjugated to the Ub-conjugating enzyme (E2) to generate an intermediate Ub-E2 complex. The Ub-ligase (E3) then catalyzes the transfer of Ub from E2 to the appropriate protein substrate. UBE2C, also designated UBCH10 in human, is an E2 ubiquitin conjugating enzyme for the anaphase promoting complex (APC), which coordinates mitosis and G1 by sequentially promoting the degradation of key cell-cycle regulators. UBE2C is overexpressed in many different types of cancers and may be a potential therapeutic target. Function: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-11'- and 'Lys-48'-linked polyubiquitination. Acts as an essential factor of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated ubiquitin ligase that controls progression through mitosis. Acts by initiating 'Lys-11'-linked polyubiquitin chains on APC/C substrates, leading to the degradation of APC/C substrates by the proteasome and promoting mitotic exit. Subunit: Component of the APC/C complex. Post-translational modifications: Autoubiquitinated by the APC/C complex, leading to its degradation by the proteasome. Its degradation plays a central role in APC/C regulation, allowing cyclin-A accumulation before S phase entry. APC/C substrates inhibit the autoubiquitination of UBE2C/UBCH10 but not its E2 function, hence APC/C remaining active until its substrates have been destroyed. Similarity: Belongs to the ubiquitin-conjugating enzyme family. Database links: UniProtKB/Swiss-Prot: O00762.1 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
